Bayer licenses early-stage KRAS cancer drug from Kumquat for up to $1.3Bnews2025-08-12T10:57:42+00:00August 12th, 2025|Endpoints News|
IO Biotech to seek FDA filing even though cancer vaccine narrowly fails pivotal skin cancer studynews2025-08-11T15:33:45+00:00August 11th, 2025|Endpoints News|
Novartis’ antibody drug ianalumab passes two Phase 3 studies in Sjögren’s diseasenews2025-08-11T10:50:04+00:00August 11th, 2025|Endpoints News|
FDA approves Boehringer’s pill for HER2-mutated lung cancernews2025-08-08T18:06:51+00:00August 8th, 2025|Endpoints News|
Assembly Bio touts Phase 1b success in herpes as Gilead buys 2.3M sharesnews2025-08-08T15:24:47+00:00August 8th, 2025|Endpoints News|
Gilead cuts several mid- and early-stage programsnews2025-08-08T15:10:27+00:00August 8th, 2025|Endpoints News|
AbbVie and Genmab seek to expand use of T cell engager Epkinlynews2025-08-08T02:05:17+00:00August 8th, 2025|Endpoints News|
Obesity pill comparison: How Novo, Lilly and others stack upnews2025-08-07T15:41:03+00:00August 7th, 2025|Endpoints News|
Chinese biotech Minghui raises $131M to advance its PD-1xVEGF bispecificnews2025-08-07T14:19:00+00:00August 7th, 2025|Endpoints News|
Eli Lilly’s obesity pill is less effective than Novo Nordisk’s, pivotal data suggestnews2025-08-07T10:28:25+00:00August 7th, 2025|Endpoints News|
